The protease of human immunodeficiency virus (HIV) is an important target for antiretroviral drug therapy. The synthesis and in vitro antiviral activity of a novel protease inhibitor, DG-35-VIII, which contains an hydroxyethylhydrazide core unit, is described. DG-35-VIII had potent activity against HIV-1 and related viruses (HIV-2 and simian immunodeficiency virus) in an acutely infected T lymphocyte line (MT-2) and was also active in cells chronically infected with HIV-1, where it inhibited processing of the Pr55gag and Pr160 gag-pal precursor proteins.
DuttaAS & MorleyJS (1975) Polypeptides. Part XIII. Preparation of a-aza-amino-acid (carbazic acid) derivatives and intermediates for the preparation of a-aza-peptides. Journal of the Chemical Society, Perkin TransactionsI, 1712–1720.
2.
FriendSCEBirchCJLordingPMMarshallJA & StuddertMA (1990) Feline immunodeficiency virus: prevalence, disease associations and isolation. Australian Veterinary Journal67: 237–243.
3.
GrobelnyDWondrakEMGalardyRE & OroszlanS (1990) Selective phosphinate transition state analogue inhibitors of protease of human immunodeficiency virus. Biochemical and Biophysical Research Communications169: 1111–1116.
4.
HuffJR (1991) HIV Protease: a novel chemotherapeutic target for AIDS. Journal of Medicinal Chemistry34:2305–2314.
5.
HunterE (1994) Macromolecular interactions in the assembly of HIV and other retroviruses. Seminars in Virology5: 7183.
6.
KempfDJNorbeckDWCodacoviLWangXCKohlbrennerWEWideburgNEPaulDAKniggeMFVasavanondaSCraig-KennardASaldivarARosenbrookWMJrClementJJPlattnerJJ & EricksonJ (1990) Structure-based, C2 symmetric inhibitors of HIV protease. Journal of Medicinal Chemistry33:2687–2689.
7.
KramerRASchaberMDSklakaAMGangulyKWang-StaalF & ReddyEP (1986) HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science231:1580–1584.
8.
LaemmliUK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature227: 680–685.
9.
LulyJRDellariaJFPlattnerJJSoderquistJL & YiN (1987) A synthesis of protected aminoalkyl epoxides from a-amino acids. Journal of Organic Chemistry52:1487–1492.
10.
NeateEVPringleRCJowettJBMHealeyDS & GustID (1987) Isolation of HIV from Australian patients with AIDS, AIDS related conditions and healthy antibody positive individuals. Australian and New Zealand Journal of Medicine17: 461–466.
11.
RichDHGreenJTothMVMarshallGR & KentSBH (1990) Hydroxyethylamine analogues of the p17/p24 substrate cleavage site are tight-binding inhibitors of HIV protease. Journal of Medicinal Chemistry33:1285–1288.
12.
RobertsNAMartinJAKinchingtonDBroadhurstAVCraigJCDuncanIBGalpinSAHandaBKKayJKrohnALambertRWMerrettJHMillsJSParkesKEBRedshawSRitchieAJTaylorDLThomasGJ & MachinPJ (1990) Rational design of peptide based HIV proteinase inhibitors. Science248: 358–361.
13.
SmythNRMcCrackenCGaskellRMCameronJMCoatesJAVGaskellCJHartCA & BennettM (1994) Susceptibility in cell culture of feline immunodeficiency virus to eighteen antiviral agents. Antimicrobial Agents and Chemotherapy34: 589–594.
14.
TachedjianGTyssenDLocarniniSGustI & BirchC (1990) Investigation of topoisomerase inhibitors for activity against human immunodeficiency virus: inhibition by coumermycin A1. Antiviral Chemistry and Chemotherapy1: 131–138.
15.
TalbottRLSpargerEELovelaceKMFitchWMPedersenNCLuciwPA & ElderJH (1989) Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proceedings of the National Academy of Sciences, USA86: 5743–5747.
16.
TomasselliAGHoweWJSawyerTKWlodawerA & HeinriksoRL (1991) The complexities of AIDS: an assessment of the HIV protease as a therapeutic target. Chimica Oggi9: 6–27.
17.
TomasselliAGThaisrivongaS & HeinriksonRL (1996) Discover)' and design of HIV protease inhibitors as drugs for the treatment of AIDS. Advances in Antiviral Drug Research2: 173–228.
18.
WeiXGhoshSKTaylorMEJohnsonVAEminiEADeutschPLifsonJDBonhoefferSNowakMAHahnBASaagMS & ShawGM (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature373: 117–122.
